Inventiva's LEGEND Trial Results to be Presented at EASL SLD Summit 2025

Inventiva, a clinical-stage biopharmaceutical company, announced that results from its LEGEND trial will be presented at the EASL SLD Summit 2025 in Estoril, Portugal. The study assessed lanifibranor combined with empagliflozin for treating metabolic dysfunction-associated steatohepatitis (MASH) and type-2 diabetes (T2D). This Phase II trial aimed to evaluate the safety and efficacy of these treatments over a 24-week period.

The trial achieved its primary goal, showing significant reductions in HbA1c levels in both treatment arms compared to placebo. Secondary endpoints, such as liver injury and glucose metabolism markers, also showed improvement. Additionally, no weight gain was observed in patients receiving the combination treatment, and no safety concerns were reported.